• Carrington Laboratories Inc., of Irving, Texas, said Nasdaq delisted the company's securities effective Thursday. Carrington said it expects to be eligible for quotation on the OTC Bulletin Board through one or more market makers. Additionally, the company's stock began trading on the Pink Sheets. Separately, Carrington signed a multiyear supply and distribution term sheet under which it would supply products, based on its DiaB and Radia brands, to Nashville, Tenn.-basedDaySpring Pharma LLC, for distribution.

• Emisphere Technologies Inc., of Tarrytown, N.Y., entered into agreements to raise about $7.57 million in a registered direct offering. Emisphere agreed to sell 2 million common shares and warrants to purchase 400,000 shares, at $3.785 per unit. The five-year warrants will be exercisable, after six months, at $3.948 per share. ThinkEquity Partners LLC is sole placement agent. The deal is expected to close Wednesday. Emisphere is developing products based on its eligen delivery technology.

• Endo Pharmaceuticals Inc., of Chadds, Ford, Pa., and Vernalis plc, of Winnerish, UK, said the FDA is extending the Aug. 19 review date on the new drug application on Frova (frovatriptan succinate) 2.5 mg tablets, for the additional indication of short-term prevention of menstrual migraine. Endo said the FDA needed more time to review the supplemental NDA, and had not requested any additional information or clinical trial data. The FDA in March also asked for a three-month extension on the review. The original PDUFA date was May 19.

• High Throughput Genomics Inc., of Tucson, Ariz., and a collaborator were awarded a two-year, $2.17 million Science Foundation Arizona Strategic Research Group grant. The company and David Galbraith, a University of Arizona Plant Sciences professor and BIO5 institute member, will work to expand and develop HTG's quantitative Nuclease Protection Assay platform into a high-density microarray to improve the quality and speed of biomarker and target identification, validation and subsequent screening and optimization of agricultural and pharmaceutical compounds.

• MediciNova Inc., of San Diego, said a Phase Ib trial of MN-221 for the treatment of preterm labor showed that target plasma concentrations were achieved with an intravenous priming followed by maintenance infusion dosing paradigm. No significant safety concerns were seen. The trial enrolled 10 healthy, pregnant volunteers who were not in labor. MN-221 is a selective beta2-adrenergic receptor agonist, which also is in a Phase IIa trial for status asthmaticus. MediciNova said its near-term focus for MN-221 is in status asthmaticus, for which trial data are expected in the fourth quarter.

• Sirtex Medical Ltd., of New South Wales, Australia, signed a licensing agreement with Synmosa Biopharma Corp., of Taiwan. The deal covers marketing in Taiwan of Sirtex's SIR-Spheres microspheres for treating advanced liver cancer. Sirtex estimated it would take one or two years to gain approval in Taiwan. Terms of the deal were not disclosed. Sirtex recently licensed the product for other areas of Asia.